Kristen Ambrose Biography and Net Worth

Kristen Ambrose joined Vertex in 2021 as Senior Vice President and Chief Accounting Officer. In this role, Ms. Ambrose is responsible for Vertex’s global functions for accounting, tax, insurance, treasury, strategic sourcing and corporate services.

Ms. Ambrose is a senior finance leader with over 20 years of experience working collaboratively with a cross-functional leadership team to deliver top tier financial results. Prior to Vertex, she held roles of increasing responsibility at Boston Scientific Corporation, a global medical device company, most recently as Vice President of Finance and Controller of the Global Endoscopy division from July 2019 to March 2021 and as Vice President of Global Internal Audit, also leading the company’s Enterprise Risk Management program, from February 2017 to June 2019. Prior to Boston Scientific Corporation, Ms. Ambrose worked in the assurance and litigation advisory practices of Ernst & Young and began her career at the Financial Accounting Standards Board (FASB).

Ms. Ambrose received her bachelor’s degree in Commerce from the University of Virginia and is a Certified Public Accountant in Massachusetts.

What is Kristen Ambrose's net worth?: The estimated net worth of Kristen Ambrose is at least $4.35 million as of February 12th, 2024. Ms. Ambrose owns 9,676 shares of Vertex Pharmaceuticals stock worth more than $4,351,587 as of November 21st. This net worth estimate does not reflect any other assets that Ms. Ambrose may own. Learn More about Kristen Ambrose's net worth.
How old is Kristen Ambrose?: Ms. Ambrose is currently 47 years old. There are 6 older executives and no younger executives at Vertex Pharmaceuticals. The oldest executive at Vertex Pharmaceuticals is Dr. Jeffrey Marc Leiden M.D., Ph.D., Executive Chairman, who is 68 years old. Learn More on Kristen Ambrose's age.
How do I contact Kristen Ambrose?: The corporate mailing address for Ms. Ambrose and other Vertex Pharmaceuticals executives is 50 NORTHERN AVENUE, BOSTON MA, 02210. Vertex Pharmaceuticals can also be reached via phone at (617) 341-6100 and via email at [email protected]. Learn More on Kristen Ambrose's contact information.
Has Kristen Ambrose been buying or selling shares of Vertex Pharmaceuticals?: Kristen Ambrose has not been actively trading shares of Vertex Pharmaceuticals in the last ninety days. Most recently, Kristen Ambrose sold 1,374 shares of the business's stock in a transaction on Monday, February 12th. The shares were sold at an average price of $420.24, for a transaction totalling $577,409.76. Following the completion of the sale, the chief accounting officer now directly owns 9,676 shares of the company's stock, valued at $4,066,242.24. Learn More on Kristen Ambrose's trading history.
Who are Vertex Pharmaceuticals' active insiders?: Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), E. Morrey Atkinson, III (EVP), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?: During the last year, insiders at the pharmaceutical company sold shares 23 times. They sold a total of 79,177 shares worth more than $36,823,476.56. The most recent insider tranaction occured on November, 15th when EVP David Altshuler sold 15 shares worth more than $7,178.40. Insiders at Vertex Pharmaceuticals own 0.2% of the company. Learn More about insider trades at Vertex Pharmaceuticals.
Information on this page was last updated on 11/15/2024.

Kristen Ambrose Insider Trading History at Vertex Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/12/2024	Sell	1,374	$420.24	$577,409.76	9,676
5/30/2023	Sell	289	$329.82	$95,317.98	6,838
2/27/2023	Sell	1,207	$287.55	$347,072.85	7,303
4/25/2022	Sell	327	$269.55	$88,142.85	3,496

Kristen Ambrose Buying and Selling Activity at Vertex Pharmaceuticals

Vertex Pharmaceuticals Company Overview

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $449.32

$445.00

$455.43

50 Day Range

MA: $475.38

$448.01

$516.74

2 Week Range

Now: $449.32

$346.29

$519.88

Volume

1,080,102 shs

Average Volume

1,187,284 shs

Market Capitalization

$115.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

“This Changes Everything” - Trump Hands Millions Massive IRS Gift

From Colonial Metals | Ad

Now it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…

>> YES! Send Me My FREE Gold Guide!

Kristen Ambrose Biography and Net Worth

What is Kristen Ambrose's net worth?

How old is Kristen Ambrose?

How do I contact Kristen Ambrose?

Has Kristen Ambrose been buying or selling shares of Vertex Pharmaceuticals?

Who are Vertex Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Vertex Pharmaceuticals?